# PollenVax Subcutaneous Immunotherapy for Mugwort Pollen-Induced Allergic Rhinitis

> **NCT07563439** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Kazakh National Agrarian University** · enrollment: 138 (estimated)

## Conditions studied

- Rhinitis Allergic

## Interventions

- **BIOLOGICAL:** Recombinant Artemisia vulgaris allergen Art v 1 with Montanide ISA-51 adjuvant
- **BIOLOGICAL:** Montanide ISA-51 placebo emulsion

## Key facts

- **NCT ID:** NCT07563439
- **Lead sponsor:** Kazakh National Agrarian University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2026-09
- **Final completion:** 2026-11
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07563439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07563439, "PollenVax Subcutaneous Immunotherapy for Mugwort Pollen-Induced Allergic Rhinitis". Retrieved via AI Analytics 2026-09-23 from https://api.ai-analytics.org/clinical/NCT07563439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*